We are live on
!
Find out more
6CM
683 Capital Management Portfolio holdings
AUM
$1.92B
1-Year Est. Return
85.52%
This Fund
S&P 500
This Quarter
Est. Return
+21.28%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$2.3B
AUM Growth
+$384M
(+20%)
Cap. Flow
+$216M
Cap. Flow
% of AUM
9.39%
Top 10 Holdings %
Top 10 Hldgs %
49.4%
Holding
255
New
116
Increased
33
Reduced
43
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kaspi.kz JSC
KSPI
|
+$20M |
| 2 |
MREO
Mereo BioPharma
MREO
|
+$19.3M |
| 3 |
Becton Dickinson
BDX
|
+$17.1M |
| 4 |
SUNC
SunocoCorp LLC
SUNC
|
+$11.8M |
| 5 |
Molina Healthcare
MOH
|
+$8.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Western Digital
WDC
|
+$29.7M |
| 2 |
uniQure
QURE
|
+$26.4M |
| 3 |
Eli Lilly
LLY
|
+$21.8M |
| 4 |
BridgeBio Pharma
BBIO
|
+$19.6M |
| 5 |
SNDK
Sandisk
SNDK
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.71% |
| 2 | Financials | 6.94% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Industrials | 3.7% |
| 5 | Technology | 3.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Amplify Energy
AMPY
$160M
| $862K | 0.04% |
+188,679
| New | +$939K |
|
152
Innovative Solutions & Support
ISSC
$370M
| $852K | 0.04% |
+45,000
| New | +$513K |
|
153
Cabaletta Bio
CABA
$442M
| $851K | 0.04% |
+388,562
| New | +$963K |
|
154
Orchestra BioMed
OBIO
$253M
| $847K | 0.04% |
+204,076
| New | +$823K |
|
|
CLYM
155
Climb Bio
CLYM
$714M
| $807K | 0.04% |
+201,652
| New | +$484K |
|
156
Quince Therapeutics
QNCX
$28.2M
| $798K | 0.03% |
+1,191
| New | +$599K |
|
157
Seres Therapeutics
MCRB
$48.4M
| $778K | 0.03% |
+52,314
| New | +$912K |
|
158
CAMP4 Therapeutics
CAMP
$208M
| $775K | 0.03% |
+126,363
| New | +$538K |
|
159
C4 Therapeutics
CCCC
$400M
| $764K | 0.03% |
+400,000
| New | +$948K |
|
160
CAE Inc. Common Shares
CAE
$8.62B
| $761K | 0.03% |
25,000
| – | – |
|
|
OYSE
161
Oyster Enterprises II Acquisition Corp
OYSE
$350M
| $758K | 0.03% |
75,000
| – | – |
|
162
Sagimet Biosciences
SGMT
$534M
| $748K | 0.03% |
+126,349
| New | +$908K |
|
163
GSI Technology
GSIT
$251M
| $738K | 0.03% |
+118,835
| New | +$848K |
|
164
vTv Therapeutics
VTVT
$135M
| $731K | 0.03% |
+18,268
| New | +$509K |
|
165
FreightCar America
RAIL
$259M
| $726K | 0.03% |
+65,596
| New | +$603K |
|
166
PUT
Scholar Rock
SRRK
$5.74B
| $714K | 0.03% |
+16,200
| New | +$608K |
|
167
Corbus Pharmaceuticals
CRBP
$177M
| $696K | 0.03% |
+85,543
| New | +$1.06M |
|
|
KLRS
168
Kalaris Therapeutics
KLRS
$99.7M
| $680K | 0.03% |
+80,590
| New | +$515K |
|
169
Galectin Therapeutics
GALT
$203M
| $676K | 0.03% |
+162,484
| New | +$856K |
|
170
Geospace Technologies
GEOS
$95.1M
| $664K | 0.03% |
+39,252
| New | +$788K |
|
171
Rani Therapeutics
RANI
$87.7M
| $658K | 0.03% |
+487,168
| New | +$735K |
|
172
Exagen
XGN
$161M
| $654K | 0.03% |
+107,571
| New | +$979K |
|
173
One Stop Systems
OSS
$325M
| $648K | 0.03% |
+90,253
| New | +$534K |
|
174
Rekor Systems
REKR
$88.2M
| $644K | 0.03% |
+467,011
| New | +$953K |
|
175
Modular Medical
MODD
$10.9M
| $642K | 0.03% |
58,737
+26,000
| +79% | +$382K |
|
Similar funds
QOP
RIL
MC
RCAG
BOH
DCM
CC
IAN
683 Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, 683 Capital Management held 255 positions worth $2.3B, up 20% from $1.91B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
683 Capital Management deployed $216M of net new capital in Q4 2025, opening 116 new positions and adding to 33 existing holdings. Its largest new stake was Kaspi.kz JSC: 265,000 shares worth $20.7M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 23% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Western Digital, an estimated $29.7M trimmed.
- 683 Capital Management's largest Q4 2025 buy was Kaspi.kz JSC: 265,000 shares worth $20.7M.
- 683 Capital Management added most to Mereo BioPharma in Q4 2025, an estimated $19.3M increase.
- 683 Capital Management's biggest Q4 2025 reduction was Western Digital, cutting an estimated $29.7M.
- 683 Capital Management fully exited Eli Lilly in Q4 2025, selling an estimated $21.8M.
- 683 Capital Management's ten largest holdings make up 49% of its $2.3B portfolio in Q4 2025.
- 683 Capital Management opened 116 new positions and closed 21 in Q4 2025.
- 683 Capital Management's portfolio value rose 20% quarter-over-quarter to $2.3B.
Based on 683 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.